Plain-English translation of NCT05107674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called that works by activating your immune system to fight cancer cells. Researchers want to find the right dose and learn whether this medication is safe and effective for people with advanced cancers—including ovarian, gastric, lung, melanoma, and other types—that haven't responded to standard treatments. The study will first test increasing doses in small groups, then expand to larger groups once a safe dose is found.
Many people with advanced cancers run out of treatment options when their disease stops responding to standard therapies or immunotherapies. This medication targets a different part of the immune system, offering hope for patients who have limited choices left.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth, either alone or combined with another cancer drug (), depending on which group you're assigned to. The study has two main phases: an initial phase where researchers test different doses to find the safest level, and a second phase where they test whether the medication works in larger groups of patients with specific cancer types. You'll have regular clinic visits for blood tests, imaging scans, and check-ins to monitor how you're responding and watch for side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States